Navigation Links
GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy

GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 - GenVec, Inc. (Nasdaq:GNVC) announced today data from two studies presented at the 97th annual meeting of the American Association of Cancer Research (AACR) that further support the use of adenovector systems to deliver the gene for tumor necrosis factor-alpha (TNF(alpha)). GenVec's lead product candidate, TNFerade(TM) biologic (TNFerade) is an adenovector, or DNA carrier, which contains the gene for TNF(alpha), a potent immune system protein with well-documented anti-cancer effects. TNFerade is currently in a pivotal Phase II/III trial for locally advanced pancreatic cancer.

GenVec researchers presented a poster entitled, "Selective delivery of tumor necrosis factor to disseminated tumors in the peritoneal cavity using targeted adenovirus vectors," (Abstract #3310) which confirmed the ability of its molecularly targeted adenovectors to selectively deliver genes to cancer cells in the peritoneal cavity in several animal models. These data demonstrated the ability of targeted vectors to penetrate tumor tissue and trigger protein expression in a dose dependent manner. This pre-clinical research suggests that tumor selective adenovectors can preferentially deliver the TNF-(alpha) gene, and holds promise as a treatment for ovarian cancer.

The mechanism of action of TNF(alpha) was the subject of a second poster presentation entitled, "The anti-tumor effects of radio-inducible TNF-alpha gene therapy target host stromal components," (Abstract #1382). In studies conducted at the University of Chicago, TNF-(alpha) delivered in an adenovector, in combination with radiation therapy, showed key effects on stromal tissues and blood vessels, both of which are critical components of human solid tumors. These results support the potential of broad activity in many tumor types.

"These results demonstrate two key findings, a potentially important mechanism of action of TNF(alpha), and the ability of adenovectors to selectively deliver the TNF(alpha) gene to cancer cells," stated C. Richter King, Ph.D., GenVec's Senior Vice President of Research. "These findings support the broad applicability of our core technology for use in the treatment of cancer," added Dr. King.

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company's product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec's lead product, TNFerade(TM) is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product cand idates, or collaborators, risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Contact

GenVec, Inc.
Sharon L. Weinstein, 240-632-5511
sweinstein@genvec.com


'"/>




Related medicine technology :

1. GenVec Announces Update of Safety and Efficacy Data from Pivotal Phase II/III PACT Study of TNFerade at ASCO
2. GenVec Presents Research on New Ad35 Adenovector at ARVO
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
(Date:2/10/2016)... 10, 2016 ALSP, Inc. announced that it has ... for Medical Affairs in preparation for its move into clinical ... PhD, CEO, stated, "We are pleased to welcome Dallas ... working with an individual of such practical knowledge and far-reaching ... drawing deeply on his broad experience and success as a ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the ... a solution that ensures the integrity of biological samples while operating at ultra-high ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Workrite Ergonomics, who ... that has evolved from humble beginnings to being an internationally recognized leader in their ... we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the importance ...
Breaking Medicine News(10 mins):